Search results
Results from the WOW.Com Content Network
The risk of venous thromboembolism with EE/CPA-containing birth control pills is similar to that with EE and gestodene-, desogestrel-, and drospirenone-containing birth control pills and about 50 to 80% higher than with EE and levonorgestrel-containing birth control pills.
[4] [7] The medication is used at a dosage of 1 mg once per week in birth control pills and 1 to 2 mg once per week in the treatment of prostate cancer. [ 12 ] [ 5 ] [ 2 ] The 1 week and 2 mg/week dosages of EES are equivalent to daily doses of 0.143 mg and 0.285 mg EES, respectively.
[126] [127] [124] Women who are not on a birth control pill or hormone therapy have a risk of VTE of about 1 to 5 out of 10,000 women per year. [ 126 ] [ 127 ] [ 116 ] [ 124 ] In women taking a birth control pill containing ethinylestradiol and a progestin, the risk of VTE is in the range of 3 to 10 out of 10,000 women per year.
Other research has found that the rate of VTE is 1 to 5 in 10,000 woman-years in women who are not pregnant or taking a birth control pill, 3 to 9 in 10,000 woman-years in women who are on a birth control pill, 5 to 20 in 10,000 women-years in pregnant women, and 40 to 65 in 10,000 women-years in postpartum women. [104]
Oral contraceptives, abbreviated OCPs, also known as birth control pills, are medications taken by mouth for the purpose of birth control.The introduction of the birth control pill ("the Pill") in 1960 revolutionized the options for contraception, sparking vibrant discussion in the scientific and social science literature and in the media.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Ulipristal acetate, sold under the brand name Ella among others, is a medication used for emergency contraception (birth control) and uterine fibroids. [1] [7] [8] As emergency contraception it should be used within 120 hours of vaginally penetrating intercourse. [1]
Mestranol/norethynodrel was the first combined oral contraceptive pill (COCP) being mestranol and norethynodrel. It sold as Enovid in the United States and as Enavid in the United Kingdom . Developed by Gregory Pincus at G. D. Searle & Company , it was first approved on June 10, 1957, by the U.S. Food and Drug Administration for treatment of ...